No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial

Carr, A; Workman, C; Carey, D; Rogers, Gary; Martin, A; Baker, D; Wand, H; Law, M; Samaras, K; Emery, S; Cooper, DA

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial

journal contribution

posted on 2024-06-05, 08:47 authored by A Carr, C Workman, D Carey, Gary RogersGary Rogers, A Martin, D Baker, H Wand, M Law, K Samaras, S Emery, DA Cooper

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial

History

Journal

Lancet

Volume

363

Pagination

429-438

Location

England

Publisher DOI

https://doi.org/10.1016/S0140-6736(04)15489-5

ISSN

0140-6736

eISSN

1474-547X

Language

English

Author URL

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000188999500009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a045e4b2bb1f2b747c68c720ec8913b7

Publication classification

C1 Refereed article in a scholarly journal

Issue

9407

Publisher

ELSEVIER SCIENCE INC

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Medicine, General & Internal General & Internal Medicine ACTIVATED RECEPTOR-GAMMA ADIPOSE-TISSUE ANTIRETROVIRAL THERAPY INSULIN SENSITIVITY INFECTED PATIENTS CASE-DEFINITION OPEN-LABEL LIPODYSTROPHY EXPRESSION DIFFERENTIATION

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial

History

Journal

Volume

Pagination

Location

Publisher DOI

ISSN

eISSN

Language

Author URL

Publication classification

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports